Erratum: Vol. 72, No. RR-2

Related Materials

In the MMWR Recommendations and Reports, “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 Influenza Season,” on page 15, in the first paragraph, the second sentence should have read, “Examples include AS01B (in Shingrix, recombinant zoster subunit vaccine) (146), AS01E (in Arexvy, respiratory syncytial virus vaccine) (147) MF59 (in Fluad Quadrivalent [aIIV4]) (56), and cytosine phosphoguanine oligodeoxynucleotide (in Heplisav-B, a recombinant hepatitis B surface antigen vaccine) (148).” In addition, on page 25, reference 147 should have read, “Arexvy [Package insert]. Durham, NC: GlaxoSmithKline; 2023.”

Suggested citation for this article: Erratum: Vol. 72, No. RR-2. MMWR Morb Mortal Wkly Rep 2023;72:1170. DOI:

MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version ( and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to